Survey on the Impact of MS Disease-Modifying Therapies |
1. Introduction
| 6% |
In late February, the Multiple Sclerosis Society of Canada will provide input on behalf of people with MS in regards to a review of the current and emerging disease-modifying therapies (DMT's) for MS taking place by the national agency that makes recommendations to provincial and territorial drug program decision makers
The national agency - Canadian Agency for Drugs and Technologies in Health (CADTH) is currently undertaking a systematic review to compare the efficacy and safety of DMT's for patients with relapsing-remitting MS and will examine their cost-effectiveness.
The review will include DMT's that are currently available in Canada (Avonex, Betaseron, Copaxone, Extavia, Gilenya, Rebif, and Tysabri) and newly emerging DMT's not yet approved in Canada (teriflunomide, dimethyl fumarate (BG-12), and alemtuzumab).
To ensure the views of Canadians affected by MS are truly represented, we are asking people with MS as well as caregivers to complete the following survey. Your answers will be incorporated into the submission to the national agency - CADTH.
Please complete the survey by Friday, March 1.
The national agency - Canadian Agency for Drugs and Technologies in Health (CADTH) is currently undertaking a systematic review to compare the efficacy and safety of DMT's for patients with relapsing-remitting MS and will examine their cost-effectiveness.
The review will include DMT's that are currently available in Canada (Avonex, Betaseron, Copaxone, Extavia, Gilenya, Rebif, and Tysabri) and newly emerging DMT's not yet approved in Canada (teriflunomide, dimethyl fumarate (BG-12), and alemtuzumab).
To ensure the views of Canadians affected by MS are truly represented, we are asking people with MS as well as caregivers to complete the following survey. Your answers will be incorporated into the submission to the national agency - CADTH.
Please complete the survey by Friday, March 1.